Cargando…

Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples

BACKGROUND: Accurate and consistent viral load (VL) quantitation of HIV type 1 (HIV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) is important for diagnosis and clinical monitoring. Assay results have to be concordant and compatible across laboratories. We evaluated the performance of thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Younhee, Roh, Juhye, Kim, Sinyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859551/
https://www.ncbi.nlm.nih.gov/pubmed/35177565
http://dx.doi.org/10.3343/alm.2022.42.4.447
_version_ 1784654486203006976
author Park, Younhee
Roh, Juhye
Kim, Sinyoung
author_facet Park, Younhee
Roh, Juhye
Kim, Sinyoung
author_sort Park, Younhee
collection PubMed
description BACKGROUND: Accurate and consistent viral load (VL) quantitation of HIV type 1 (HIV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) is important for diagnosis and clinical monitoring. Assay results have to be concordant and compatible across laboratories. We evaluated the performance of three Aptima assays (Hologic, San Diego, CA, USA) and compared their VL values with corresponding cobas 6800 assay (Roche Diagnostics, Mannheim, Germany) results, using 840 clinical samples. METHODS: The correlation between VL results obtained using the two assays was evaluated in terms of analytical sensitivity, precision/reproducibility, linearity, and cross-reactivity. Agreement rates were determined using kappa statistics. The overall agreement of VL values was examined using Passing–Bablok regression analysis. RESULTS: All CVs were within 5%; the assays had good precision for detecting all three viruses. The linearity of quantitation assessed using three AccuSpan linearity panels (Seracare, Milford, MA, USA), was excellent for the Aptima assays. For HIV-1 and HCV, the results of both assays showed excellent agreement (κ=0.89 and 0.90, respectively) while for HBV, the results showed good agreement (κ=0.69). For analytical sensitivity, the VLs required for a 100% detection rate of HIV-1, HBV, and HCV were 20 copies/mL, 7.5 IU/mL, and 5.0 IU/mL, respectively. The results for HIV-1, HBV, and HCV obtained using both assays correlated strongly (R(2)=0.97, 0.93, and 0.95, respectively). CONCLUSIONS: The cobas 6800 and Aptima assays, with fully automated and high-throughput molecular platforms for HIV-1, HBV, and HCV VL measurements, show good analytical performance and a strong correlation between results. The study results suggest that the assays can be used interchangeably for long-term monitoring of chronic infections.
format Online
Article
Text
id pubmed-8859551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Society for Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-88595512022-07-01 Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples Park, Younhee Roh, Juhye Kim, Sinyoung Ann Lab Med Original Article BACKGROUND: Accurate and consistent viral load (VL) quantitation of HIV type 1 (HIV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) is important for diagnosis and clinical monitoring. Assay results have to be concordant and compatible across laboratories. We evaluated the performance of three Aptima assays (Hologic, San Diego, CA, USA) and compared their VL values with corresponding cobas 6800 assay (Roche Diagnostics, Mannheim, Germany) results, using 840 clinical samples. METHODS: The correlation between VL results obtained using the two assays was evaluated in terms of analytical sensitivity, precision/reproducibility, linearity, and cross-reactivity. Agreement rates were determined using kappa statistics. The overall agreement of VL values was examined using Passing–Bablok regression analysis. RESULTS: All CVs were within 5%; the assays had good precision for detecting all three viruses. The linearity of quantitation assessed using three AccuSpan linearity panels (Seracare, Milford, MA, USA), was excellent for the Aptima assays. For HIV-1 and HCV, the results of both assays showed excellent agreement (κ=0.89 and 0.90, respectively) while for HBV, the results showed good agreement (κ=0.69). For analytical sensitivity, the VLs required for a 100% detection rate of HIV-1, HBV, and HCV were 20 copies/mL, 7.5 IU/mL, and 5.0 IU/mL, respectively. The results for HIV-1, HBV, and HCV obtained using both assays correlated strongly (R(2)=0.97, 0.93, and 0.95, respectively). CONCLUSIONS: The cobas 6800 and Aptima assays, with fully automated and high-throughput molecular platforms for HIV-1, HBV, and HCV VL measurements, show good analytical performance and a strong correlation between results. The study results suggest that the assays can be used interchangeably for long-term monitoring of chronic infections. Korean Society for Laboratory Medicine 2022-07-01 2022-07-01 /pmc/articles/PMC8859551/ /pubmed/35177565 http://dx.doi.org/10.3343/alm.2022.42.4.447 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Younhee
Roh, Juhye
Kim, Sinyoung
Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title_full Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title_fullStr Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title_full_unstemmed Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title_short Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
title_sort performance evaluation of the aptima assays in comparison with the cobas 6800 assays for the detection of hiv-1, hbv, and hcv in clinical samples
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859551/
https://www.ncbi.nlm.nih.gov/pubmed/35177565
http://dx.doi.org/10.3343/alm.2022.42.4.447
work_keys_str_mv AT parkyounhee performanceevaluationoftheaptimaassaysincomparisonwiththecobas6800assaysforthedetectionofhiv1hbvandhcvinclinicalsamples
AT rohjuhye performanceevaluationoftheaptimaassaysincomparisonwiththecobas6800assaysforthedetectionofhiv1hbvandhcvinclinicalsamples
AT kimsinyoung performanceevaluationoftheaptimaassaysincomparisonwiththecobas6800assaysforthedetectionofhiv1hbvandhcvinclinicalsamples